The Prevail phase three trial will enroll 9,000 patients with established ASCVD and risk-enhancing factors, aiming for a baseline LDL of approximately 100 mg/dL to demonstrate a potential MACE reduction of over 20%.

“so that's where you've got 9 000 patients and are these people with uh existing ascvd as well so it's also secondary prevention yes there it's hardcore ascvd and we've even entered a lot of risk enhancing factors into this trial because we understand that the higher the risk the easier it is to show a benefit and we also strive for a baseline LDL of around a hundred because if your Baseline LDL is around a hundred and your LDL lowering is 50 then your absolute difference is 50 milligram per deciliter you have a 27 maze reduction”